-
Je něco špatně v tomto záznamu ?
The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study
V. D. Palumbo, M. Romeo, A. Marino Gammazza, F. Carini, P. Damiani, G. Damiano, S. Buscemi, A. I. Lo Monte, A. Gerges-Geagea, A. Jurjus, G. Tomasello
Jazyk angličtina Země Česko
Typ dokumentu časopisecké články, randomizované kontrolované studie
Free Medical Journals od 1998
Medline Complete (EBSCOhost) od 2007-06-01
ROAD: Directory of Open Access Scholarly Resources od 2001
Odkazy
PubMed
27623957
DOI
10.5507/bp.2016.044
domovská stránka časopisu
Knihovny.cz E-zdroje
- MeSH
- analýza rozptylu MeSH
- antiflogistika nesteroidní terapeutické užití MeSH
- Bifidobacterium bifidum MeSH
- dospělí MeSH
- dvojitá slepá metoda MeSH
- kombinovaná farmakoterapie MeSH
- Lactobacillus acidophilus MeSH
- Lactobacillus salivarius MeSH
- lidé středního věku MeSH
- lidé MeSH
- mesalamin terapeutické užití MeSH
- probiotika terapeutické užití MeSH
- senioři MeSH
- ulcerózní kolitida farmakoterapie MeSH
- výsledek terapie MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- senioři MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- randomizované kontrolované studie MeSH
AIM: Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. METHOD: Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. RESULTS: All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. CONCLUSIONS: A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.
- 000
- 00000naa a2200000 a 4500
- 001
- bmc17016662
- 003
- CZ-PrNML
- 005
- 20170519133136.0
- 007
- ta
- 008
- 170516s2016 xr f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.5507/bp.2016.044 $2 doi
- 035 __
- $a (PubMed)27623957
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a xr
- 100 1_
- $a Palumbo, Vincenzo Davide $u Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy; Department of Surgical, Oncological and Stomatological Disciplines, School of Medicine, University of Palermo, Palermo, Italy
- 245 14
- $a The long-term effects of probiotics in the therapy of ulcerative colitis: A clinical study / $c V. D. Palumbo, M. Romeo, A. Marino Gammazza, F. Carini, P. Damiani, G. Damiano, S. Buscemi, A. I. Lo Monte, A. Gerges-Geagea, A. Jurjus, G. Tomasello
- 520 9_
- $a AIM: Intestinal dysbiosis seems to be the leading cause of inflammatory bowel diseases, and probiotics seems to represent the proper support against their occurrence. Actually, probiotic blends and anti-inflammatory drugs represent a weapon against inflammatory bowel diseases. The present study evaluates the long-term (2 years) effects of combination therapy (mesalazine plus a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4) on ulcerative colitis activity. METHOD: Sixty patients with moderate-to-severe ulcerative colitis were enrolled: 30 of them were treated with a single daily oral administration of mesalazine 1200 mg; 30 patients received a single daily oral administration of mesalazine 1200 mg and a double daily administration of a probiotic blend of Lactobacillus salivarius, Lactobacillus acidophilus and Bifidobacterium bifidus strain BGN4. The treatment was carried out for two years and the clinical response evaluated according to the Modified Mayo Disease Activity Index. RESULTS: All patients treated with combination therapy showed better improvement compared to the controls. In particular, the beneficial effects of probiotics were evident even after two years of treatment. CONCLUSIONS: A long-term treatment modality of anti-inflammatory drugs and probiotics is viable and could be an alternative to corticosteroids in mild-to moderate ulcerative colitis.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a senioři $7 D000368
- 650 _2
- $a analýza rozptylu $7 D000704
- 650 _2
- $a antiflogistika nesteroidní $x terapeutické užití $7 D000894
- 650 _2
- $a Bifidobacterium bifidum $7 D000069985
- 650 _2
- $a ulcerózní kolitida $x farmakoterapie $7 D003093
- 650 _2
- $a dvojitá slepá metoda $7 D004311
- 650 _2
- $a kombinovaná farmakoterapie $7 D004359
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a Lactobacillus acidophilus $7 D007779
- 650 _2
- $a Lactobacillus salivarius $7 D000069996
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mesalamin $x terapeutické užití $7 D019804
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a probiotika $x terapeutické užití $7 D019936
- 650 _2
- $a výsledek terapie $7 D016896
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a randomizované kontrolované studie $7 D016449
- 700 1_
- $a Romeo, Marcello $u Department of Experimental Biomedicine and Clinical Neuroscience, School of Medicine, University of Palermo, Palermo, Italy
- 700 1_
- $a Marino Gammazza, Antonella $u Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy; Department of Experimental Biomedicine and Clinical Neuroscience, School of Medicine, University of Palermo, Palermo, Italy
- 700 1_
- $a Carini, Francesco $u Department of Experimental Biomedicine and Clinical Neuroscience, School of Medicine, University of Palermo, Palermo, Italy; P. Giaccone University Hospital, Palermo, Italy
- 700 1_
- $a Damiani, Provvidenza $u P. Giaccone University Hospital, Palermo, Italy
- 700 1_
- $a Damiano, Giuseppe $u Department of Experimental Biomedicine and Clinical Neuroscience, School of Medicine, University of Palermo, Palermo, Italy
- 700 1_
- $a Buscemi, Salvatore $u Department of Experimental Biomedicine and Clinical Neuroscience, School of Medicine, University of Palermo, Palermo, Italy
- 700 1_
- $a Lo Monte, Attilio Ignazio $u Department of Experimental Biomedicine and Clinical Neuroscience, School of Medicine, University of Palermo, Palermo, Italy; P. Giaccone University Hospital, Palermo, Italy
- 700 1_
- $a Gerges-Geagea, Alice $u Department of Experimental Biomedicine and Clinical Neuroscience, School of Medicine, University of Palermo, Palermo, Italy; Department of Anatomy, Cell Biology and Physiology, School of Medidcine, Aamerican University of Beirut, Beirut, Lebanon
- 700 1_
- $a Jurjus, Abdo $u Department of Anatomy, Cell Biology and Physiology, School of Medidcine, Aamerican University of Beirut, Beirut, Lebanon
- 700 1_
- $a Tomasello, Giovanni $u Euro-Mediterranean Institute of Science and Technology (IEMEST), Palermo, Italy; Department of Experimental Biomedicine and Clinical Neuroscience, School of Medicine, University of Palermo, Palermo, Italy; P. Giaccone University Hospital, Palermo, Italy
- 773 0_
- $w MED00012606 $t Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czech Republic $x 1213-8118 $g Roč. 160, č. 3 (2016), s. 372-377
- 856 41
- $u http://biomed.papers.upol.cz/ $y domovská stránka časopisu
- 910 __
- $a ABA008 $b A 1502 $c 958 $y 4 $z 0
- 990 __
- $a 20170516 $b ABA008
- 991 __
- $a 20170517145502 $b ABA008
- 999 __
- $a ok $b bmc $g 1205808 $s 977471
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2016 $b 160 $c 3 $d 372-377 $e 20160913 $i 1213-8118 $m Biomedical papers of the Medical Faculty of the University Palacký, Olomouc Czech Republic $n Biomed. Pap. Fac. Med. Palacký Univ. Olomouc Czech Repub. (Print) $x MED00012606
- LZP __
- $b NLK118 $a Pubmed-20170516